J 2011

Dynamics of Glial Fibrillary Acidic Protein During Traumatic Brain Injury in Children

ŽUREK, Jiří a Michal FEDORA

Základní údaje

Originální název

Dynamics of Glial Fibrillary Acidic Protein During Traumatic Brain Injury in Children

Vydání

The Journal of Trauma: Injury, Infection and Critical Care, Lippincott Williams & Wilkins, 2011, 0022-5282

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.478

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/11:00055261

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Glial fibrillary acidic protein; brain injury; outcome; children

Příznaky

Mezinárodní význam
Změněno: 2. 2. 2012 09:45, Mgr. Michal Petr

Anotace

V originále

Backgrounds: Glial fibrillary acidic protein (GFAP) is a monomeric intermediate filament protein found in the astroglial cytoskeleton and is not found outside the central nervous system. It is a brain-specific protein that is released after traumatic brain injury (TBI). Methods: This prospective study enrolled 59 children who had TBI, as verified by computed tomography. Daily GFAP measurement began at admission (< 12 hours after trauma) and continued for 6 days. Blood samples were analyzed for GFAP by enzyme-linked immunosorbent assay. Outcome was assessed using the Glasgow Outcome Scale (GOS) at 6 months after injury. Results: The median serum levels of GFAP at admission were 7.47 ng/mL in patients who died, compared with 0.12 ng/mL in patients who survived (p = 0.002). GFAP levels were significantly higher in patients who had a poor outcome 6 months after injury than in those who were alive or had good outcome (p < 0.001). The area under the receiver operating characteristic curve for GFAP was 0.833 for day 0 and 0.884 for day 2. Conclusions: These results suggest that determination of serum levels of GFAP may add to the clinical assessment of the primary damage and prediction of outcome after severe TBI.